Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead’s Yescarta Growth Continues, But Momentum Slowed

Executive Summary

Yescarta brought in $75m in the third quarter, up 10% sequentially, and well above the $20m tallied by competitor Kymriah. Gilead also saw continued HIV sales growth, with HCV sales in line with expectations.


Advertisement

Related Content

Gilead Maintains Optimistic Outlook For Yescarta Despite Slow Growth
Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead
The Case For CAR-T Grows As Responses Hold Up Longer Term
Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV
Eight Things To Know From Novartis' Third Quarter Call
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain
Milligan’s Retirement Means New CEO For New Gilead
Yescarta One Of Few Gilead Bright Spots, And Now It Has A Competing CAR-T

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124061

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel